Faeth Therapeutics (FTH) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Immuneering (IMRX) over the past year, losing 9.6% versus a loss of 53.7%. Over five years, IMRX leads with a -85.0% price change compared with -95.0% for FTH. Immuneering is the larger company by market cap ($218.9 million vs $203.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTH | IMRX |
|---|---|---|
| Share price | $7.88 | $3.38 |
| Market cap | $203.65M | $218.90M |
| 1-day change | -9.32% | -2.03% |
| YTD return | -26.15% | -48.63% |
| 1-year return | -9.64% | -53.70% |
| 5-year return | -94.96% | -85.00% |
| EPS (TTM) | $-22.50 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-21.09M | $-56.02M |
| 52-week high | $42.14 | $8.48 |
| 52-week low | $7.45 | $3.29 |
| Distance from 52-week high | -81.30% | -60.14% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +612.56% | +402.96% |
| Average volume | 500.25K | 747.66K |
| Shares outstanding | 25.84M | 64.76M |
| Employees | 29 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed IMRX by 44.1 percentage points over the past year.
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
FTH vs IMRX FAQ
Which is bigger, Faeth Therapeutics or Immuneering?
Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $203.65M for Faeth Therapeutics (FTH).
Which stock has performed better over the past year, FTH or IMRX?
FTH returned -9.64% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Faeth Therapeutics and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.